{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T07:16:33Z","timestamp":1782285393846,"version":"3.54.5"},"reference-count":59,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"EMD Serono Research & Development Institute, Inc., Billerica, MA, USA, an affiliate of Merck KGaA"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Targ Oncol"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1007\/s11523-025-01162-4","type":"journal-article","created":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T11:51:42Z","timestamp":1751370702000},"page":"743-754","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["A Podcast on Real-World Evidence with Avelumab First-Line Maintenance and Treatment Sequencing in Locally Advanced or Metastatic Urothelial Carcinoma"],"prefix":"10.1007","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3965-3394","authenticated-orcid":false,"given":"Petros","family":"Grivas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen H.","family":"Moon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,1]]},"reference":[{"key":"1162_CR1","first-page":"15","volume":"8","author":"K Saginala","year":"2020","unstructured":"Saginala K, Barsouk A, Aluru JS, Rawla P, Padala SA, Barsouk A. Epidemiology of bladder cancer. Med Sci (Basel). 2020;8:15.","journal-title":"Med Sci (Basel)."},{"key":"1162_CR2","unstructured":"National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Bladder Cancer. V5.2024. https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/bladder.pdf."},{"key":"1162_CR3","unstructured":"National Cancer Institute. SEER Cancer Stat Facts: Bladder Cancer. https:\/\/seer.cancer.gov\/statfacts\/html\/urinb.html. Accessed 21 Nov 2024."},{"key":"1162_CR4","first-page":"12","volume":"74","author":"RL Siegel","year":"2024","unstructured":"Siegel RL, Giaquinto AN, Jemal A. Cancer statistics, 2024. CA Cancer J Clin. 2024;74:12\u201349.","journal-title":"CA Cancer J Clin"},{"key":"1162_CR5","volume":"23","author":"PJ Vlachostergios","year":"2020","unstructured":"Vlachostergios PJ, Faltas BM, Carlo MI, Nassar AH, Alaiwi SA, Sonpavde G. The emerging landscape of germline variants in urothelial carcinoma: implications for genetic testing. Cancer Treat Res Commun. 2020;23:100165.","journal-title":"Cancer Treat Res Commun."},{"key":"1162_CR6","doi-asserted-by":"crossref","first-page":"93279","DOI":"10.18632\/oncotarget.21565","volume":"8","author":"X Sui","year":"2017","unstructured":"Sui X, Lei L, Chen L, Xie T, Li X. Inflammatory microenvironment in the initiation and progression of bladder cancer. Oncotarget. 2017;8:93279\u201394.","journal-title":"Oncotarget"},{"key":"1162_CR7","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1007\/s40273-014-0194-2","volume":"32","author":"C Yeung","year":"2014","unstructured":"Yeung C, Dinh T, Lee J. The health economics of bladder cancer: an updated review of the published literature. Pharmacoeconomics. 2014;32:1093\u2013104.","journal-title":"Pharmacoeconomics"},{"key":"1162_CR8","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1007\/s00345-009-0395-z","volume":"27","author":"KD Sievert","year":"2009","unstructured":"Sievert KD, Amend B, Nagele U, Schilling D, Bedke J, Horstmann M, et al. Economic aspects of bladder cancer: what are the benefits and costs? World J Urol. 2009;27:295\u2013300.","journal-title":"World J Urol"},{"key":"1162_CR9","doi-asserted-by":"crossref","first-page":"3173","DOI":"10.1200\/JCO.1999.17.10.3173","volume":"17","author":"DF Bajorin","year":"1999","unstructured":"Bajorin DF, Dodd PM, Mazumdar M, Fazzari M, McCaffrey JA, Scher HI, et al. Long-term survival in metastatic transitional-cell carcinoma and prognostic factors predicting outcome of therapy. J Clin Oncol. 1999;17:3173\u201381.","journal-title":"J Clin Oncol"},{"key":"1162_CR10","doi-asserted-by":"crossref","first-page":"3012","DOI":"10.1002\/cncr.28146","volume":"119","author":"MD Galsky","year":"2013","unstructured":"Galsky MD, Moshier E, Krege S, Lin CC, Hahn N, Ecke T, et al. Nomogram for predicting survival in patients with unresectable and\/or metastatic urothelial cancer who are treated with cisplatin-based chemotherapy. Cancer. 2013;119:3012\u20139.","journal-title":"Cancer"},{"key":"1162_CR11","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/j.annonc.2024.03.001","volume":"35","author":"T Powles","year":"2024","unstructured":"Powles T, Bellmunt J, Comperat E, De Santis M, Huddart R, Loriot Y, et al. ESMO Clinical Practice Guideline interim update on first-line therapy in advanced urothelial carcinoma. Ann Oncol. 2024;35:485\u201390.","journal-title":"Ann Oncol"},{"key":"1162_CR12","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2022.103683","volume":"174","author":"J Bellmunt","year":"2022","unstructured":"Bellmunt J, Valderrama BP, Puente J, Grande E, Bolos MV, Lainez N, et al. Recent therapeutic advances in urothelial carcinoma: a paradigm shift in disease management. Crit Rev Oncol Hematol. 2022;174:103683.","journal-title":"Crit Rev Oncol Hematol"},{"key":"1162_CR13","unstructured":"US Food and Drug Administration. FDA approves avelumab for urothelial carcinoma maintenance treatment. 2020. https:\/\/www.fda.gov\/drugs\/drug-approvals-and-databases\/fda-approves-avelumab-urothelial-carcinoma-maintenance-treatment. Accessed 21 Nov 2024."},{"key":"1162_CR14","unstructured":"US Food and Drug Administration. FDA approves nivolumab in combination with cisplatin and gemcitabine for unresectable or metastatic urothelial carcinoma. 2024. https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-nivolumab-combination-cisplatin-and-gemcitabine-unresectable-or-metastatic-urothelial. Accessed 21 Nov 2024."},{"key":"1162_CR15","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1056\/NEJMoa2312117","volume":"390","author":"T Powles","year":"2024","unstructured":"Powles T, Valderrama BP, Gupta S, Bedke J, Kikuchi E, Hoffman-Censits J, et al. Enfortumab vedotin and pembrolizumab in untreated advanced urothelial cancer. N Engl J Med. 2024;390:875\u201388.","journal-title":"N Engl J Med"},{"key":"1162_CR16","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1056\/NEJMoa2002788","volume":"383","author":"T Powles","year":"2020","unstructured":"Powles T, Park SH, Voog E, Caserta C, Valderrama BP, Gurney H, et al. Avelumab maintenance therapy for advanced or metastatic urothelial carcinoma. N Engl J Med. 2020;383:1218\u201330.","journal-title":"N Engl J Med"},{"key":"1162_CR17","doi-asserted-by":"crossref","first-page":"3486","DOI":"10.1200\/JCO.22.01792","volume":"41","author":"T Powles","year":"2023","unstructured":"Powles T, Park SH, Caserta C, Valderrama BP, Gurney H, Ullen A, et al. Avelumab first-line maintenance for advanced urothelial carcinoma: results from the JAVELIN Bladder 100 trial after \u22652 years of follow-up. J Clin Oncol. 2023;41:3486\u201392.","journal-title":"J Clin Oncol"},{"key":"1162_CR18","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.1056\/NEJMoa2309863","volume":"389","author":"MS van der Heijden","year":"2023","unstructured":"van der Heijden MS, Sonpavde G, Powles T, Necchi A, Burotto M, Schenker M, et al. Nivolumab plus gemcitabine-cisplatin in advanced urothelial carcinoma. N Engl J Med. 2023;389:1778\u201389.","journal-title":"N Engl J Med"},{"issue":"12 Suppl","key":"1162_CR19","first-page":"Abstract CO68","volume":"27","author":"M Kearney","year":"2024","unstructured":"Kearney M, Musat M, Moradian H, Barth\u00e9l\u00e9my P. Effectiveness and safety of avelumab first-line maintenance (1LM) in locally advanced or metastatic urothelial carcinoma (la\/mUC): a systematic literature review (SLR) and meta-analysis (MA). Value Health. 2024;27(12 Suppl):Abstract CO68.","journal-title":"Value Health."},{"key":"1162_CR20","doi-asserted-by":"crossref","DOI":"10.1016\/j.clgc.2024.102238","volume":"22","author":"P Grivas","year":"2024","unstructured":"Grivas P, Barata P, Moon H, Gupta S, Hutson T, Sternberg CN, et al. Avelumab first-line maintenance for locally advanced or metastatic urothelial carcinoma: results from the real-world US PATRIOT-II study. Clin Genitourin Cancer. 2024;22:102238.","journal-title":"Clin Genitourin Cancer"},{"key":"1162_CR21","doi-asserted-by":"crossref","first-page":"5662","DOI":"10.3390\/curroncol31090420","volume":"31","author":"HH Moon","year":"2024","unstructured":"Moon HH, Kearney M, Mahmoudpour SH, Ike C, Morris V, Rava A, et al. Real-world treatment patterns, sequencing, and outcomes in patients with locally advanced or metastatic urothelial carcinoma receiving avelumab first-line maintenance in the United States. Curr Oncol. 2024;31:5662\u201376.","journal-title":"Curr Oncol"},{"issue":"16 Suppl","key":"1162_CR22","doi-asserted-by":"crossref","first-page":"Abstract e16621","DOI":"10.1200\/JCO.2024.42.16_suppl.e16621","volume":"42","author":"KR Carson","year":"2024","unstructured":"Carson KR, Ike C, Mahmoudpour SH, Monzon S, Fragkogianni S, Kearney M. Real-world (rw) treatment (tx) patterns, sequencing, and outcomes in US patients (pts) with locally advanced or metastatic urothelial cancer (la\/mUC) treated with avelumab first-line maintenance (1LM). J Clin Oncol. 2024;42(16 Suppl):Abstract e16621.","journal-title":"J Clin Oncol"},{"key":"1162_CR23","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/j.euo.2024.09.014","volume":"8","author":"P Barth\u00e9l\u00e9my","year":"2025","unstructured":"Barth\u00e9l\u00e9my P, Thibault C, Flechon A, Gross-Goupil M, Voog E, Eymard JC, et al. Real-world study of avelumab first-line maintenance treatment in patients with advanced urothelial carcinoma in France: overall results from the noninterventional AVENANCE study and analysis of outcomes by second-line treatment. Eur Urol Oncol. 2025;8:407\u201316.","journal-title":"Eur Urol Oncol."},{"key":"1162_CR24","volume":"5","author":"L Antonuzzo","year":"2024","unstructured":"Antonuzzo L, Maruzzo M, De Giorgi U, Santini D, Tambaro R, Buti S, et al. READY: REAl-world Data from an Italian compassionate use program of avelumab first-line maintenance for locallY advanced or metastatic urothelial carcinoma. ESMO Real World Data Dig Oncol. 2024;5:100068.","journal-title":"ESMO Real World Data Dig Oncol."},{"key":"1162_CR25","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1016\/j.clgc.2023.06.008","volume":"21","author":"DR Bakaloudi","year":"2023","unstructured":"Bakaloudi DR, Talukder R, Lin GI, Makrakis D, Diamantopoulos LN, Tripathi N, et al. Response and outcomes of maintenance avelumab after platinum-based chemotherapy (PBC) in patients with advanced urothelial carcinoma (aUC): \u201creal world\u201d experience. Clin Genitourin Cancer. 2023;21:584\u201393.","journal-title":"Clin Genitourin Cancer"},{"issue":"Suppl 2","key":"1162_CR26","first-page":"Abstract 1996P","volume":"35","author":"E Kikuchi","year":"2024","unstructured":"Kikuchi E, Nagata M, Ito T, Sato M, Ogi M, Morita M, et al. Primary analysis of post-marketing surveillance (PMS) data for avelumab maintenance therapy in patients (pts) with curatively unresectable urothelial carcinoma (UC) in Japan. Ann Oncol. 2024;35(Suppl 2):Abstract 1996P.","journal-title":"Ann Oncol"},{"key":"1162_CR27","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1111\/iju.15473","volume":"31","author":"E Kikuchi","year":"2024","unstructured":"Kikuchi E, Hayakawa N, Nakayama M, Uno M, Nakatsu H, Kitagawa C, et al. J-AVENUE: a retrospective, real-world study evaluating patient characteristics and outcomes in patients with advanced urothelial carcinoma treated with avelumab first-line maintenance therapy in Japan. Int J Urol. 2024;31:859\u201367.","journal-title":"Int J Urol"},{"key":"1162_CR28","doi-asserted-by":"crossref","first-page":"1403120","DOI":"10.3389\/fonc.2024.1403120","volume":"14","author":"SH Park","year":"2024","unstructured":"Park SH, Shin SJ, Rha SY, Beom SH, Seo HK, Keam B, et al. Avelumab first-line maintenance treatment in patients with locally advanced or metastatic urothelial carcinoma: real-world results from a Korean expanded access program. Front Oncol. 2024;14:1403120.","journal-title":"Front Oncol"},{"key":"1162_CR29","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1093\/oncolo\/oyad174","volume":"28","author":"MA Bilen","year":"2023","unstructured":"Bilen MA, Robinson SB, Schroeder A, Peng J, Kim R, Liu FX, et al. Clinical and economic outcomes in patients with metastatic urothelial carcinoma receiving first-line systemic treatment (the IMPACT UC I study). Oncologist. 2023;28:790\u20138.","journal-title":"Oncologist"},{"key":"1162_CR30","doi-asserted-by":"crossref","first-page":"357.e11","DOI":"10.1016\/j.urolonc.2023.03.012","volume":"41","author":"AK Morgans","year":"2023","unstructured":"Morgans AK, Galsky MD, Wright P, Hepp Z, Chang N, Willmon CL, et al. Real-world treatment patterns and clinical outcomes with first-line therapy in patients with locally advanced\/metastatic urothelial carcinoma by cisplatin-eligibility. Urol Oncol. 2023;41:357.e11-357.e21.","journal-title":"Urol Oncol"},{"issue":"6 Suppl","key":"1162_CR31","doi-asserted-by":"crossref","first-page":"Abstract 508","DOI":"10.1200\/JCO.2023.41.6_suppl.508","volume":"41","author":"SS Sridhar","year":"2023","unstructured":"Sridhar SS, Powles T, Gupta S, Climent M\u00c1, Aragon-Ching JB, Sternberg CN, et al. Avelumab first-line (1L) maintenance for advanced urothelial carcinoma (UC): long-term follow-up from the JAVELIN Bladder 100 trial in subgroups defined by 1L chemotherapy regimen and analysis of overall survival (OS) from start of 1L chemotherapy. J Clin Oncol. 2023;41(6 Suppl):Abstract 508.","journal-title":"J Clin Oncol"},{"key":"1162_CR32","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2023.102050","volume":"8","author":"P Grivas","year":"2023","unstructured":"Grivas P, Grande E, Davis ID, Moon HH, Grimm MO, Gupta S, et al. Avelumab first-line maintenance treatment for advanced urothelial carcinoma: review of evidence to guide clinical practice. ESMO Open. 2023;8:102050.","journal-title":"ESMO Open."},{"key":"1162_CR33","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1093\/aje\/kwm324","volume":"167","author":"S Suissa","year":"2008","unstructured":"Suissa S. Immortal time bias in pharmaco-epidemiology. Am J Epidemiol. 2008;167:492\u20139.","journal-title":"Am J Epidemiol"},{"issue":"16 Suppl","key":"1162_CR34","doi-asserted-by":"crossref","first-page":"Abstract 4560","DOI":"10.1200\/JCO.2022.40.16_suppl.4560","volume":"40","author":"J Bellmunt","year":"2022","unstructured":"Bellmunt J, Powles T, Duran MAC, Sridhar SS, Gurney H, Costa N, et al. Long-term outcomes in patients with advanced urothelial carcinoma (UC) who received avelumab first-line (1L) maintenance with or without second-line (2L) treatment: exploratory analyses from JAVELIN Bladder 100. J Clin Oncol. 2022;40(16 Suppl):Abstract 4560.","journal-title":"J Clin Oncol"},{"key":"1162_CR35","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.eururo.2023.03.030","volume":"84","author":"P Grivas","year":"2023","unstructured":"Grivas P, Park SH, Voog E, Caserta C, Gurney H, Bellmunt J, et al. Avelumab first-line maintenance therapy for advanced urothelial carcinoma: comprehensive clinical subgroup analyses from the JAVELIN Bladder 100 phase 3 trial. Eur Urol. 2023;84:95\u2013108.","journal-title":"Eur Urol"},{"key":"1162_CR36","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.eururo.2023.08.001","volume":"85","author":"SS Sridhar","year":"2024","unstructured":"Sridhar SS, Powles T, Climent Duran MA, Park SH, Massari F, Thiery-Vuillemin A, et al. Avelumab first-line maintenance for advanced urothelial carcinoma: analysis from JAVELIN Bladder 100 by duration of first-line chemotherapy and interval before maintenance. Eur Urol. 2024;85:154\u201363.","journal-title":"Eur Urol"},{"issue":"Suppl 2","key":"1162_CR37","doi-asserted-by":"crossref","first-page":"S1207","DOI":"10.1016\/j.annonc.2023.09.1020","volume":"34","author":"S Gupta","year":"2023","unstructured":"Gupta S, Climent Duran MA, Sridhar S, Powles TB, Bellmunt J, Tyroller K, et al. Avelumab first-line (1L) maintenance for advanced urothelial carcinoma (aUC): long-term outcomes from the JAVELIN Bladder 100 trial in older patients (pts). Ann Oncol. 2023;34(Suppl 2):S1207 (Abstract 2371P).","journal-title":"Ann Oncol"},{"issue":"4 Suppl","key":"1162_CR38","doi-asserted-by":"crossref","first-page":"Abstract 600","DOI":"10.1200\/JCO.2024.42.4_suppl.600","volume":"42","author":"JB Aragon-Ching","year":"2024","unstructured":"Aragon-Ching JB, Petrylak DP, Sridhar SS, Gupta S, Grivas P, Powles T, et al. Avelumab first-line (1L) maintenance for advanced urothelial carcinoma (aUC): long-term outcomes from the JAVELIN Bladder 100 trial in patients (pts) with high body mass index (BMI). J Clin Oncol. 2024;42(4 Suppl):Abstract 600.","journal-title":"J Clin Oncol"},{"issue":"16 Suppl","key":"1162_CR39","doi-asserted-by":"crossref","first-page":"Abstract 4566","DOI":"10.1200\/JCO.2024.42.16_suppl.4566","volume":"42","author":"J Bellmunt","year":"2024","unstructured":"Bellmunt J, Powles T, Park SH, Voog E, P\u00e9rez Valderrama B, Gurney H, et al. Avelumab first-line maintenance (1LM) for advanced urothelial carcinoma (aUC): long-term outcomes from JAVELIN Bladder 100 in patients (pts) with low tumor burden. J Clin Oncol. 2024;42(16 Suppl):Abstract 4566.","journal-title":"J Clin Oncol"},{"issue":"16 Suppl","key":"1162_CR40","doi-asserted-by":"crossref","first-page":"Abstract 4516","DOI":"10.1200\/JCO.2023.41.16_suppl.4516","volume":"41","author":"J Bellmunt","year":"2023","unstructured":"Bellmunt J, Aragon-Ching JB, Climent MA, Sridhar S, Powles T, Cislo P, et al. Long-term safety of avelumab first-line (1L) maintenance for advanced urothelial carcinoma (aUC) in the JAVELIN Bladder 100 trial. J Clin Oncol. 2023;41(16 Suppl):Abstract 4516.","journal-title":"J Clin Oncol"},{"key":"1162_CR41","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/j.eururo.2022.04.016","volume":"83","author":"P Grivas","year":"2023","unstructured":"Grivas P, Kopyltsov E, Su PJ, Parnis FX, Park SH, Yamamoto Y, et al. Patient-reported outcomes from JAVELIN Bladder 100: avelumab first-line maintenance plus best supportive care versus best supportive care alone for advanced urothelial carcinoma. Eur Urol. 2023;83:320\u20138.","journal-title":"Eur Urol"},{"issue":"4 Suppl","key":"1162_CR42","doi-asserted-by":"crossref","first-page":"Abstract 581","DOI":"10.1200\/JCO.2024.42.4_suppl.581","volume":"42","author":"P Grivas","year":"2024","unstructured":"Grivas P, Aragon-Ching JB, Bellmunt J, Loriot Y, Sridhar SS, Su P-J, et al. Avelumab first-line maintenance (1LM) for advanced urothelial carcinoma (aUC): long-term patient-reported outcomes (PROs) in the phase 3 JAVELIN Bladder 100 trial. J Clin Oncol. 2024;42(4 Suppl):Abstract 581.","journal-title":"J Clin Oncol"},{"issue":"Suppl 2","key":"1162_CR43","first-page":"Abstract P251","volume":"69","author":"T Powles","year":"2024","unstructured":"Powles T, Gupta S, Sridhar S, Bellmunt J, Tyroller K, Hoffman J, et al. Avelumab first-line maintenance (1LM) in advanced urothelial carcinoma (aUC): analysis of quality-adjusted time without symptoms or toxicity (Q-TWiST) in older patients (pts) from the JAVELIN Bladder 100 trial. Eur Urol Open Sci. 2024;69(Suppl 2):Abstract P251.","journal-title":"Eur Urol Open Sci."},{"key":"1162_CR44","doi-asserted-by":"crossref","first-page":"1844","DOI":"10.3390\/curroncol30020143","volume":"30","author":"M Tang","year":"2023","unstructured":"Tang M, Pearson SA, Simes RJ, Chua BH. Harnessing real-world evidence to advance cancer research. Curr Oncol. 2023;30:1844\u201359.","journal-title":"Curr Oncol"},{"key":"1162_CR45","first-page":"287","volume":"72","author":"LT Penberthy","year":"2022","unstructured":"Penberthy LT, Rivera DR, Lund JL, Bruno MA, Meyer AM. An overview of real-world data sources for oncology and considerations for research. CA Cancer J Clin. 2022;72:287\u2013300.","journal-title":"CA Cancer J Clin"},{"key":"1162_CR46","doi-asserted-by":"crossref","first-page":"2139","DOI":"10.1200\/JCO.23.01030","volume":"42","author":"JM Unger","year":"2024","unstructured":"Unger JM, Shulman LN, Facktor MA, Nelson H, Fleury ME. National estimates of the participation of patients with cancer in clinical research studies based on commission on cancer accreditation data. J Clin Oncol. 2024;42:2139\u201348.","journal-title":"J Clin Oncol"},{"key":"1162_CR47","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1002\/cpt.1658","volume":"107","author":"BK Beaulieu-Jones","year":"2020","unstructured":"Beaulieu-Jones BK, Finlayson SG, Yuan W, Altman RB, Kohane IS, Prasad V, et al. Examining the use of real-world evidence in the regulatory process. Clin Pharmacol Ther. 2020;107:843\u201352.","journal-title":"Clin Pharmacol Ther"},{"issue":"Suppl 1","key":"1162_CR48","first-page":"Abstract P236","volume":"57","author":"RJ Jones","year":"2023","unstructured":"Jones RJ, Shah Y, Birtle A, Challapalli A, Chan J, Enting D, et al. Avelumab first-line (1L) maintenance therapy for advanced urothelial cancer: real-world early clinical experience in the UK. Eur Urol Open Sci. 2023;57(Suppl 1):Abstract P236.","journal-title":"Eur Urol Open Sci."},{"issue":"2 Suppl","key":"1162_CR49","first-page":"Abstract V33-02","volume":"63","author":"PJ Goebell","year":"2024","unstructured":"Goebell PJ, Radkowski R, M\u00fcller L, Ghasemi U, Gr\u00fcnwald V, Deger S, et al. First-line maintenance therapy in patients with locally advanced or metastatic urothelial carcinoma in routine care in Germany: interim results of the prospective CARAT registry. Die Urologie. 2024;63(2 Suppl):Abstract V33-02.","journal-title":"Die Urologie."},{"issue":"Suppl 2","key":"1162_CR50","first-page":"Abstract P245","volume":"69","author":"L Goncalves","year":"2024","unstructured":"Goncalves L, Guedes H, Fortuna A, Lemos T, Gramaca J, Mourao N, et al. Avelumab in advanced urothelial carcinoma: insights from a multicenter Portuguese study on efficacy, safety, and treatment sequencing. Eur Urol Open Sci. 2024;69(Suppl 2):Abstract P245.","journal-title":"Eur Urol Open Sci."},{"issue":"S1","key":"1162_CR51","first-page":"Abstract 58","volume":"20","author":"A-J Inderjeeth","year":"2024","unstructured":"Inderjeeth A-J, Wakeling S, O\u2019Haire S, Gibbs P, Wong L-M, Zhang A, et al. Real-world avelumab uptake for first-line (1L) treatment for metastatic urothelial bladder cancer (mUC). Asia Pac J Clin Oncol. 2024;20(S1):Abstract 58.","journal-title":"Asia Pac J Clin Oncol"},{"issue":"4 Suppl","key":"1162_CR52","doi-asserted-by":"crossref","first-page":"Abstract 558","DOI":"10.1200\/JCO.2024.42.4_suppl.558","volume":"42","author":"S Bracarda","year":"2024","unstructured":"Bracarda S, Antonuzzo L, Maruzzo M, Santini D, Tambaro R, Buti S, et al. Subgroup analyses from READY: real-world data from an Italian compassionate use program (CUP) of avelumab first-line maintenance (1LM) treatment for locally advanced or metastatic urothelial carcinoma (la\/mUC). J Clin Oncol. 2024;42(4 Suppl):Abstract 558.","journal-title":"J Clin Oncol"},{"key":"1162_CR53","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.2217\/fon-2023-0298","volume":"20","author":"M Kearney","year":"2024","unstructured":"Kearney M, Zhang L, Hubscher E, Musat M, Harricharan S, Wilke T. Undertreatment in patients with advanced urothelial cancer: systematic literature review and meta-analysis. Future Oncol. 2024;20:1123\u201337.","journal-title":"Future Oncol"},{"issue":"4 Suppl","key":"1162_CR54","doi-asserted-by":"crossref","first-page":"Abstract 537","DOI":"10.1200\/JCO.2024.42.4_suppl.537","volume":"42","author":"A Nizam","year":"2024","unstructured":"Nizam A, Jindal T, Jiang CY, Alhalabi O, Bakaloudi DR, Talukder R, et al. Outcomes in patients (pts) with advanced urothelial carcinoma (aUC) treated with enfortumab vedotin (EV) after switch maintenance avelumab (MAv) in the UNITE study. J Clin Oncol. 2024;42(4 Suppl):Abstract 537.","journal-title":"J Clin Oncol"},{"key":"1162_CR55","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1007\/s11523-024-01099-0","volume":"19","author":"O Fiala","year":"2024","unstructured":"Fiala O, Massari F, Basso U, Giannatempo P, Grande E, Buti S, et al. Enfortumab vedotin following platinum chemotherapy and avelumab maintenance in patients with metastatic urothelial carcinoma: a retrospective data from the ARON-2(EV) study. Target Oncol. 2024;19:905\u201315.","journal-title":"Target Oncol"},{"key":"1162_CR56","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1056\/NEJMoa2035807","volume":"384","author":"T Powles","year":"2021","unstructured":"Powles T, Rosenberg JE, Sonpavde GP, Loriot Y, Duran I, Lee JL, et al. Enfortumab vedotin in previously treated advanced urothelial carcinoma. N Engl J Med. 2021;384:1125\u201335.","journal-title":"N Engl J Med"},{"key":"1162_CR57","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1016\/j.annonc.2023.08.016","volume":"34","author":"JE Rosenberg","year":"2023","unstructured":"Rosenberg JE, Powles T, Sonpavde GP, Loriot Y, Duran I, Lee JL, et al. EV-301 long-term outcomes: 24-month findings from the phase III trial of enfortumab vedotin versus chemotherapy in patients with previously treated advanced urothelial carcinoma. Ann Oncol. 2023;34:1047\u201354.","journal-title":"Ann Oncol"},{"key":"1162_CR58","doi-asserted-by":"crossref","first-page":"3419","DOI":"10.21873\/anticanres.17162","volume":"44","author":"A Minato","year":"2024","unstructured":"Minato A, Furubayashi N, Tomoda T, Masaoka H, Song Y, Hori Y, et al. Clinical outcomes of enfortumab vedotin in advanced urothelial carcinoma with prior avelumab versus pembrolizumab therapy. Anticancer Res. 2024;44:3419\u201326.","journal-title":"Anticancer Res"},{"issue":"10-c Suppl","key":"1162_CR59","first-page":"Abstract N6","volume":"30","author":"C Ike","year":"2024","unstructured":"Ike C, Wangia Dixon R, Crowe C, Venkataraman M, Moon H, Morris V, et al. Health care resource utilization and direct medical costs among patients with metastatic urothelial carcinoma receiving first-line systemic treatment and avelumab first-line maintenance: results from the IMPACT UC-III study. J Manag Care Spec Pharm. 2024;30(10-c Suppl):Abstract N6.","journal-title":"J Manag Care Spec Pharm"}],"container-title":["Targeted Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11523-025-01162-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11523-025-01162-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11523-025-01162-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,23]],"date-time":"2025-09-23T02:07:07Z","timestamp":1758593227000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11523-025-01162-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,1]]},"references-count":59,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["1162"],"URL":"https:\/\/doi.org\/10.1007\/s11523-025-01162-4","relation":{},"ISSN":["1776-2596","1776-260X"],"issn-type":[{"value":"1776-2596","type":"print"},{"value":"1776-260X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,1]]},"assertion":[{"value":"10 June 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 July 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 August 2025","order":3,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":4,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Article note related to podcast and transcript updated","order":5,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This podcast was sponsored by EMD Serono Research & Development Institute, Inc., Billerica, MA, USA, an affiliate of Merck KGaA.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"The authors received no honoraria related to the development of this publication. Petros Grivas is an Editorial Board member of Targeted Oncology. Petros Grivas was not involved in the selection of peer reviewers for the article nor any of the subsequent editorial decisions. Petros Grivas in the last 2 years reports consulting with AbbVie, Asieris Pharmaceuticals, Astellas Pharma, AstraZeneca, Bicycle Therapeutics, Bristol Myers Squibb, Daiichi Sankyo, EMD Serono Research & Development Institute, Inc., Billerica, MA, USA, an affiliate of Merck KGaA, Fresenius Kabi, Gilead Sciences, ImmunityBio, Janssen, MSD, Pfizer, Replimune, Roche, and Strata Oncology and institutional research funding from Acrivon Therapeutics, ALX Oncology, Bristol Myers Squibb, EMD Serono Research & Development Institute, Inc., Billerica, MA, USA, an affiliate of Merck KGaA, Gilead Sciences, Genentech, MSD, and QED Therapeutics. Helen H. Moon has received honoraria from Merck and Pfizer and institutional research funding from Amgen, Apollomics, Arcus Biosciences, AVEO, Bristol Myers Squibb, Genentech, HUYA Bioscience International, Nektar, Prometheus, RevImmune, and Seagen.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Publish"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of Data and Material"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"Petros Grivas and Helen H. Moon contributed equally to all aspects of the development of this podcast, including concept and design, drafting of the outline, and interpretation of the data discussed. Both authors read and approved the final transcript.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author Contributions"}}]}}